Citi analyst P.J. Juvekar sees now as the perfect time to buy Chemours Co CC stock, as he upgraded his rating to Buy with a $45 price target.
“We think the recent pullback offers a good entry point. Our investment thesis is primarily based on: 1) Excellent regulation driven growth for fluorochemicals, particularly Opteon adoption and 2) To a lesser extent on a gradual improvement in the TiO2 cycle,” Juvekar said (check out his track record here).
Specifically highlighting the Opteon opportunity, Juvekar pointed out how Opteon HFO adoption has been much stronger than expected. "More than 50% new US and 100% of EU vehicles transitioned to HFO technology by the end of 2016 with expected doubling of vehicle adoption by year-end to 50mm.”
Further, Juvekar sees upsides coming “from regulation-driven replacement of older refrigerants and optionality to raise the dividend or buyback shares following near-term payment of the PFOA liability settlement of $335mm.”
To stay up to date on Chemours latest metrics, earnings updates, and exclusive news visit Benzinga Pro.
Related Links:
The Simple Case For Being A Chemours Bull Chemours' Reduced Litigation Risk Removes Susquehanna's Objections To The Stock
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.